TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01281462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
Study: NCT04411550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX11
Description: healthy volunteers receive HLX11 (420mg) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-Perjeta(Pertuzumab)
Description: healthy volunteers receive CN-Perjeta (420mg) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Perjeta(Pertuzumab)
Description: healthy volunteers receive EU-Perjeta (420mg) once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Perjeta(Pertuzumab)
Description: healthy volunteers receive US-Perjeta (420mg) once
Study: NCT00622986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an extract of Cimicifuga Foetida L.
Description: Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an extract of Cimicifuga Foetida L.
Description: Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each patient will be given placebo of 2 tablets each day for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each patient will be given placebo of 2 tablets each day for 3 months.
Study: NCT01096563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for inhalation via Turbuhaler, JSMAD.
Study: NCT03706287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib 8mg + AP/PC
Description: anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib 10mg + AP/PC
Description: anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib 12mg + AP/PC
Description: anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib + AP/PC
Description: anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
Study: NCT01489514

Intervention type: OTHER
Intervention: Epicutaneous skin prick testing
Description: Epicutaneous skin prick testing will be performed utilizing the following extracts:~1. Histamine control purchased from Greer.~2. Saline control purchased from Greer.~3. Standard Peanut Extract purchased from Greer.~4. Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A \& T.~5. Sterile extract prepared from roasted \& blanched but untreated peanuts. This is prepared by North Carolina A \& T.~6. Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A \& T. This is not classified as a drug and is~7. Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~8. Sterile extracts containing peanuts that have been treated with alcalase
Study: NCT00105443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Study: NCT01072370

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cord Blood Infusion
Description: red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Intravenous Sham
Description: intravenous infusion of 5% dextrose, ¼ normal saline solution
Study: NCT02561091

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.4 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.8 mg/ml
Study: NCT04455555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003( the name of rotigotine)
Description: LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
Study: NCT02875353

Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler Endoscopic Probe
Description: A colon length catheter (probe).
Study: NCT00577408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot naltrexone
Description: On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Naltrexone
Description: For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
Study: NCT04245761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sonidor®
Description: Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
Study: NCT03824431

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic esophageal biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic esophageal biopsies
Study: NCT04422886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation (tDCS)
Description: 20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation (sham)
Description: 1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
Study: NCT04455555

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
Study: NCT02930993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-mesothelin CAR T cells
Description: Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
Study: NCT02543528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens 1
Description: One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens 2
Description: One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens 3
Description: One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A (Reusable)
Description: One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A (1-Day)
Description: 2-week contact lens adaptation period wearing prior to randomization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A (1-Day)
Description: 2-week contact lens adaptation period wearing prior to randomization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A (1-Day)
Description: 2-week contact lens adaptation period wearing prior to randomization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A (1-Day)
Description: 2-week contact lens adaptation period wearing prior to randomization
Study: NCT02977169

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PORT
Description: 3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
Study: NCT00650754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 25 mg PO TID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01408147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online postpartum weight control
Description: The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
Study: NCT04170595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB221,2 mg/kg
Description: Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB221,6 mg/kg
Description: Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin,6 mg/kg
Description: Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB221,8mg/kg
Description: Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB221:2mg/kg and Capecitabi:1000mg/kg
Description: GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin:2mg/kg and Capecitabin:1000mg/kg
Description: Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
Study: NCT01042600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube insertion
Description: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion
Description: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
Study: NCT00742339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin plus albumin
Description: The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine plus octreotide plus human albumin
Description: Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
Study: NCT04541004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet
Description: Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
Study: NCT02258360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic hypothermia
Description: Therapeutic hypothermia with a target temperature between 32-34°C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Description: Therapeutic hypothermia with a target temperature between 32-34°C.
Study: NCT00691483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken orally twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline tablets, 1 mg taken orally twice daily for 12 weeks
Study: NCT00049673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study: NCT03839459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120mg of Denosumab will be administered subcutaneously once every 4 weeks
Study: NCT03116646

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chewing evaluation
Description: Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
Study: NCT01091701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo cultured adult allogenic MSCs
Description: Single IV dose of allogenic MSCs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte-A
Description: Single IV dose of Plasmalyte-A
Study: NCT00976066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A Assessing GSK1521498
Description: Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B Assessing GSK1521498
Description: The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part C Assessing Naltrexone
Description: A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
Study: NCT04035317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aesculus Hippocastanum / Horse Chestnut
Description: Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
Study: NCT00132132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral education program
Description: Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
Study: NCT06038786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Training
Description: A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resilience Training
Description: A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
Study: NCT03023943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.